PA
ZYNE

Perceptive Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Perceptive Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-130,700
Closed -$1.32M – 159
2017
Q3 		$1.32M Buy
+130,700
New +$1.38M 0.05% 101
2017
Q2 		– Sell
-251,328
Closed -$5M – 163
2017
Q1 		$5.05M Sell
251,328
-590,800
-70% -$11.7M 0.29% 61
2016
Q4 		$13.1M Sell
842,128
-26,769
-3% -$361K 0.93% 29
2016
Q3 		$11.3M Buy
868,897
+19,547
+2% +$186K 0.73% 33
2016
Q2 		$5.82M Hold
849,350
– – 0.4% 53
2016
Q1 		$8.03M Buy
849,350
+290,904
+52% +$2.35M 0.7% 36
2015
Q4 		$5.62M Sell
558,446
-20,904
-4% -$277K 0.42% 52
2015
Q3 		$8.29M Buy
+579,350
New +$14.2M 0.66% 39

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Perceptive Advisors's ZYNE Position: Q4 2017 in Review

Perceptive Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2017, closing a stake of 130,700 shares — an estimated $1.32M sold.

Perceptive Advisors first reported a position in ZYNE in Q3 2015 and held it in 8 quarters. The position peaked at $13.1M in Q4 2016. 64 funds tracked by Wall St. Rank hold ZYNE as of Q4 2017.

  • Perceptive Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2017 after selling out during the quarter.
  • Perceptive Advisors sold 130,700 Zynerba Pharmaceuticals, Inc shares in Q4 2017, an estimated $1.32M.
  • Perceptive Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 8 quarters.
  • Perceptive Advisors's Zynerba Pharmaceuticals, Inc position peaked at $13.1M in Q4 2016.
  • 64 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2017.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.